138113-75-4

Upstream product

• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 108-93-0 cyclohexanol 
• 1046140-44-6 (4-cyclohexyloxyphenyl)acetic acid methyl ester 

Downstream Products

• 1331775-49-5 1-(4-cyclohexyloxyphenyl)hexan-2-one 
• 1331775-50-8 3-(4-cyclohexyloxyphenyl)-2-hydroxy-4-oxooctanoic acid ethyl ester 
• 1331776-44-3 3-(4-cyclohexyloxyphenyl)-4-oxo-2-trifluoromethyl-oct-2-enoic acid methyl ester 
• 1331776-47-6 4-[6-butyl-5-(4-cyclohexyloxyphenyl)-4-trifluoromethylpyridazin-3-yloxy]piperidine-1-carboxylic acid tert-butyl ester 
• 1331776-45-4 6-butyl-5-(4-cyclohexyloxy-phenyl)-4-trifluoromethyl-2H-pyridazin-3-one 
• 1331776-46-5 3-butyl-6-chloro-4-(4-cyclohexyloxyphenyl)-5-trifluoromethylpyridazine 

Relevant academic research and scientific papers

PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF

The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.

Novel benzimidazole derivatives as selective CB2 agonists

The preparation and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety are reported. They showed binding affinities up to 1 nM towards the CB2 receptor with partial to full agonist potencies. They also demonstrated good to excellent selectivity (>1000-fold) over the CB1 receptor.